More about Science
Choose a therapeutic area to find related scientific content
Diabetes
Neurology
Rare Diseases
Rare Blood Disorders
Explore Content
Explore the most recently added content
Prescribing Information can be found through the links in the Product Cards at the bottom of the page
AUBAGIO® (teriflunomide) Overview: Efficacy (Brain Health) and Real-World (Patient-Reported Outcomes, Adherence, Effectiveness) - Prof. Jiwon Oh
Aubagio® (teriflunomide): MoA and Safety - Prof. Patrick Vermersch
Fabry Disease & Cardiology
Fabry Disease and Nephrology
Preserving Brain Health: Going Beyond Focal Inflammation | Part 1 - Prof. Gavin Giovannoni
Preserving Brain Health: Going Beyond Focal Inflammation | Part 2 - Prof. Gavin Giovannoni
Preserving Brain Health: Going Beyond Focal Inflammation | Part 3 - Prof. Jiwon Oh
Signs and Symptoms of Pompe disease
Treatment and Specialist Treatment Centres in the UK for Pompe disease
What is Pompe disease?
Support for your Patients
Discover the selection of support materials for patients from different therapeutic areas
Patient Support | Diabetes
Toujeo® Coach | Toujeo® (insulin glargine 300 units/mL)
Our Products
---Copy.png/jcr:content/AUBAGIO_logo_RGB%20(1)%20-%20Copy.png){kind=logo}
Prescribing Information GB
Prescribing Information NI
MAT-XU-2200676 (v3.0)
Date of preparation: August 2022
MAT-GB-2105812 (v2.0)
Date of preparation: August 2022
MAT-XU-2201444 (v2.0)
Date of preparation: August 2022
.png/jcr:content/Lemtrada-triangle-logo-product-card%20(1).png){kind=logo}
Prescribing Information GB
Prescribing Information NI
MAT-XU-2200680 (v2.0)
Date of preparation: August 2022
.png/jcr:content/Myozyme-logo%20(1).png){kind=logo}
MAT-GB-2105179 (v3.0)
Date of preparation: August 2022
MAT-GB-2105435 (v2.0)
Date of preparation: August 2022
▼ This drug is subject to additional monitoring, the reporting of suspected adverse reactions associated with this drug is a priority.
MAT-GB-2105264 (v3.0)
Date of preparation: September 2022
